VEGFA and neoplasm: Notably, preclinical data suggest that VEGF pathway inhibition can reduce M2-TAM prevalence or reprogram them toward a pro-inflammatory M1 phenotype, thereby improving tumor microenvironment immunogenicity and potentially enhancing response to ICIs [24].